Anthony Molloy - 04 Jan 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Chief Lgl & Compliance Officer
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
04 Jan 2022
Net transactions value
$0
Form type
4
Filing time
10 Jan 2022, 16:28:45 UTC
Previous filing
17 Dec 2021
Next filing
20 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Award $0 +2,000 +13% $0.000000 17,774 04 Jan 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PCRX Stock Option (Right to Buy) Award $0 +5,000 $0.000000 5,000 04 Jan 2022 Common Stock 5,000 $61.60 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units that vest in four equal annual installments beginning on January 2, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2 Includes 224 shares of common stock acquired under the issuer's employee stock purchase plan in December 2021.
F3 The stock option vests and becomes exercisable as to 25% of the option shares on December 7, 2022, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.